The Biden administration on Friday released the next round of prescription drugs selected for Medicare price negotiations, including Ozempic — the blockbuster diabetes drug that’s also used for weight loss. The drug has faced public backlash over its high price, fueling demand for cheaper alternatives.

WASHINGTON — Medicare officials announced plans to negotiate the prices of blockbuster diabetes and weight loss drugs Ozempic and Wegovy, further complicating big decisions the Trump administration will have to make about how to cover the medications.

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations, the Biden administration announced Friday.

The Centers for Medicare and Medicaid Services (CMS) has selected 15 more drugs for Medicare price negotiation, announcing the selection two weeks ahead of schedule. Administration officials did not share which drugs had been selected,

On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare.